Insider trade

Kura Oncology (KURA): Chief Scientific Officer exercised options on 30K units

Francis Burrows, Chief Scientific Officer at Kura Oncology, reported an option exercise of 30K units.

30K
Derivative units
Traded
Sep 24, 2026
Filed
Sep 25, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 24, 2026, Kura Oncology, Inc. (the “ Company ”) entered into a Second Amended and Restated Executive Employment Agreement with Troy E. Wilson, Ph.D., J.D., the Company’s Chairman, President and Chief Executive Officer (the “ Wilson Agreement ”) to, among other things, modify certain severance provisions.”
  2. Aug 12, 2026Company filing · Form 8-K · ResultsReported its results
  3. Sep 8, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective as of September 8, 2026, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointed Jennifer Fulk as the Company’s Chief Financial Officer, principal financial officer (replacing Troy E. Wilson, Ph.D., J.D. solely with respect to such role) and principal accounting officer (replacing Thomas Doyle solely with respect to such role).”
  4. Sep 24, 2026InsiderOfficer sold ~$225K of KURA shares in the open market

What came next

  1. Sep 28, 2026Insider · 5 peopleInsiders: 6 sales (~$519K)
  2. Sep 29, 2026Insider · 3 peopleInsiders: 3 sales (~$515K)
  3. Oct 27, 20265% stakeBlackRock, Inc. reported a passive stake (13G) of 8.9%
  4. Nov 10, 2026Company filing · Form 8-K · ResultsReported its results
  5. Nov 13, 2026Insider · First insider buy since Sep 2025CEO purchased ~$754K of KURA shares in the open market
  6. Nov 16, 20265% stakeBVF PARTNERS L P/IL reported a passive stake (13G) of 7.5%
  7. Nov 16, 2026InsiderCEO purchased ~$750K of KURA shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Kura Oncology

For Kura Oncology, OQRO holds 17 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KURA page.

Other recent filings by Francis Burrows, Chief Scientific Officer

The full history of Francis Burrows, Chief Scientific Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Kura Oncology (KURA) insider traded, and how much?

Francis Burrows, Chief Scientific Officer at Kura Oncology, reported an option exercise of 30K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Sep 24, 2026. Filed: Sep 25, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Kura Oncology recently?

For Kura Oncology, OQRO holds 17 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the KURA page.

Does this mean KURA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Kura Oncology

Everything OQRO holds on this company is on its KURA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data